Stability of blood coagulation factors and inhibitors in blood drawn into half-strength citrate anticoagulant

Vox Sanguinis

Volumn 71, Issue 2, 1996, Pages 97-102

  Suontaka, A M ^a   Akerblom O ^b   Blomback M ^a   Eriksson, L ^b   Hogman C F ^b   Payrat, J M ^c  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^c Baxter R and D Europe   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9; BLOOD CLOTTING INHIBITOR; CITRIC ACID;

ARTICLE; BLOOD STORAGE; ERYTHROCYTE PRESERVATION; HUMAN; KALLIKREIN KININ SYSTEM; NORMAL HUMAN; PRIORITY JOURNAL;

EID: 0029802251     PISSN: 00429007     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1423-0410.1996.7120097.x     Document Type: Article

References (32)

1. Prowse C, Waterston YG, Dawes J, Farrugia A: Studies on the procurement of blood coagulation factor VIII: In vitro studies on blood components prepared in half-strength citrate anticoagulant. Vox Sang 1987;52:257-264.
2. Griffin B, Bell K, Prowse C: Studies on the procurement of blood coagulation factor VIII: In vivo studies on blood components prepared in half-strength citrate anticoagulant. Vox Sang 1988;54:193-198.
3. Griffin B, Bell K, Prowse C: Studies on the procurement of blood coagulation factor VIII: In vitro studies on blood components prepared in half-strenght citrate anticoagulant 18 hours after phlebotomy. Vox Sang 1988;55:9-13.
4. Farrugia A, Douglas S, James J, Whyte G: Red cell and platelet concentrates from blood collected into half-strength citrate anticoagulant: Improved maintenance of red cell 2,3-diphosphoglycerate in half-citrate red cells. Vox Sang 1992;63:31-38.
5. Högman CF, Eriksson L, Gong J, Payrat JM, Debrauwere J: Half-strength citrate CPD and new additive solutions for improved blood preservation. 1. Studies of six experimental solutions. Transfus Med 1993;3:43-50.
6. Högman CF, Eriksson L, Gong J, Vikholm K, Debrauwere J, Payrat JM: Half-strength citrate CPD and new additive solutions for improved blood preservation. 2. The effect of storage at ambient temperature before component preparation and different means of supplying glucose to the red cells. Transfus Med 1993;3:211-222.
7. Högman CF, Eriksson L, Gong J, Högman AB, Vikholm K, Debrauwere J, Payrat JM, Stewart M: Half-strength citrate CPD combined with a new additive solution for improved storage of red blood cells suitable for clinical use. Vox Sang 1993;65:271-278.
8. Rosén S, Andersson M, Blombäck M, Hägglund U, Larrieu MJ, Wolf M, Boyer C, Rothschild C, Nilsson IM, Sjörin E, Vinazzer H: Clinical application of a chromogenic substrate method for determination of factor VIII activity. Thromb Haemostas 1985;54:818-823.
9. Abildgaard U, Lie M, Odegård OR: Antithrombin (heparin cofactor) assay with new chromogenic substrates (S-2238 and Chromozym TH). Thromb Res 1977;11:549-553.
10. Ödegård OR, Try K, Andersson TR: Protein C: An automated activity assay. Haemostasis 1987;17:109-113.
11. Wiman B, Rånby M: Determination of soluble fibrin in plasma by a rapid and quantitative spectrophotometric assay. Thromb Haemostas 1986;55:189-193.
12. Blombäck M, Chmielewska J, Netré C, Åkerblom O: Activation of blood coagulation, fibrinolytic and kallikrein systems during storage of plasma. Vox Sang 1984;47:335-342.
13. Nossel HL, Yudelmann I, Canfield RE, Butler VP Jr, Spanondis K, Wilner GD, Qureshi GD: Measurement of fibrinopeptide A in human blood. J Clin Invest 1974;54:43-53.
14. Kockum C, Frebelius S: Rapid radio immunoassay of human fibrinopeptide A: Removal of crossreacting fibrinogen with bentonite. Thromb Res 1980;19:589-598.
15. Hardisty RM, Macpherson JC: A one-stage factor VIII (anti-haemophilic globulin) assay and its use on venous and capillary plasma. Thromb Diathes Haemorrh 1962;7:215-229.
16. Vermylen C, de Vreker RA, Verstraete M: A rapid enzymatic method for assay of fibrinogen fibrin polymerization time (FPT test). Clin Chim Acta 1963;8:418-124.
17. Wiman B, Nilsson T: A simple method for the determination of C1-esterase inhibitor activity in plasma. Clin Chim Acta 1983;128:359-366.
18. Pelzer H, Schwarz A, Heimburger N: Determination of human thrombin-antithrombin III complex in plasma with an enzyme-linked immunosorbent assay. Thromb Haemostas 1988; 59:101-106.
19. Hughes C, Thomas KB, Schiff P, Herrington RW, Polacsek EE, McGrath KM: Effect of delayed blood processing on the yield of factor VIII in cryoprecipitate and factor VIII concentrate. Transfusion 1988;28:566-570.
20. Pieterz RNI, de Korte D, Reesink HW, Dekker WJA, van den Ende A, Loos JA: Storage of whole blood for up to 24 hours at ambient temperature prior to component preparation. Vox Sang 1989;56:145-150.
21. Pflugshaupt R, Kurt G: FPA content: A criterion of quality for plasma as factor VIII source. Vox Sang 1983;45:224-232.
22. Carlebjörk G, Biombäck M, Åkerblom O: Improvement of plasma quality as raw material for factor VIII:C concentrates: Storage of whole blood and plasma and interindividual plasma levels of fibrinopeptide A. Vox Sang 1983;45: 233-242.
23. Skjönsberg OH, Kierulf P, Fagerhol MK, Godal HC: Thrombin generation during collection and storage of blood. Vox Sang 1986;50:33-37.
24. Åkerblom O, Bremme K, Dackland ÅL, Fatah K, Suontaka AM, Biomback M: Freezing technique and quality of fresh frozen plasma. Infusionstherapie 1992;19:283-287.
25. Weiss HJ: A study of the cation- and pH-dependent stability of factors V and VIII in plasma. Thromb Diath Haemorrh 1965;14:32-51.
26. Mikaelsson ME, Foreman N, Oswaldsson UM: Human factor VIII: A calcium-linked protein complex. Blood 1983;62:1006-1015.
27. Rock GA, Craickshank WH, Tackaberry ES, Ganz PR, Palmer DS: Stability of VIII:C in plasma: The dependence on protease activity and calcium. Thromb Res 1983;29:521-535.
28. Prowse CV: Donation procedure: collection lesion, fibrinopeptide A, and factor VIII; in Smit Sibinga CTh, Das PC, Seidl S (eds): Plasma Fractionation and Blood Transfusion. Developments in Hematology and Immunology. Dordrecht, Martinus Nijhoff, 1985, pp 25-32.
29. Blombäck B, Blombäck M: Purification and stabilization of factor V. Nature 1963;198:886-887.
30. McIntosh RV, Foster PR: The effect of solution formulation on the stability and surface interactions of factor VIII during plasma fractionation. Transfus Sci 1990;11:55-66.
31. Duguid J, Winkelman L, Feldman P, Brady A-M: The effect of citrate anticoagulants on apheresed plasma. Transfus Sci 1989;10:287-293.
32. Evans D, Walker T, Evans H: Pilot scale (300 kg) fractionation of plasma for factor VIII and factor IX. Transfus Sci 1989;10:313-319.